{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"comment":"DLT not applicable for Phase 2 participants","groupId":"OG006","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"description":"Rate of dose limiting toxicities (DLT)","groups":[{"description":"Single administration dose cohorts, given in a single intravenous infusion of CAR-T cells. Rimiducid may be administered as indicated.","id":"OG000","title":"Phase 1: P-BCMA-101 CAR-T Cells"},{"description":"Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.","id":"OG001","title":"Phase 1 P-BCMA-101 CAR-T Cells (Cohort A)"},{"description":"Single dose given across three intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.","id":"OG002","title":"Phase 1 P-BCMA-101 CAR-T Cells (Cohort B)"},{"description":"Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.","id":"OG003","title":"Phase 1 P-BCMA-101 CAR-T Cells With Comb.Therapy (Cohort R)"},{"description":"Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before apheresis. Rimiducid may be administered as indicated.","id":"OG004","title":"Phase 1 P-BCMA-101 CAR-T Cells With Comb.Therapy (Cohort RP)"},{"description":"Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.","id":"OG005","title":"Phase 1 P-BCMA-101 CAR-T Cells With Comb.Therapy (Cohort RIT)"},{"description":"CAR-T cells administered via intravenous infusion as a total dose","id":"OG006","title":"Phase 2: P-BCMA-101 CAR-T Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Baseline through Day 28","title":"Phase 1: Maximum Tolerated Dose of P-BCMA-101","type":"PRIMARY","unitOfMeasure":"Participants"}